Of note, in diseases with a high risk of thrombosis, such as lung cancer (36) and lupus anticoagulants (53), we have previously observed a decrease in the total ITGA2B level in the platelet proteome, but not to this extent, underlining the magnitude of thrombotic dysregulation in COVID-19. Here, ITGA2B is linked to lung cancer.